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Abstract Duffy antigen/receptor for chemokines (DARC)
is a glycosylated seven-transmembrane protein acting as a
blood group antigen, a chemokine binding protein and a
receptor for Plasmodium vivax malaria parasite. It is present
on erythrocytes and endothelial cells of postcapillary ven-
ules. The N-terminal extracellular domain of the Duffy
glycoprotein carries Fy
a/Fy
b blood group antigens and Fy6
linear epitope recognized by monoclonal antibodies. Previ-
ously, we have shown that recombinant Duffy protein
expressed in K562 cells has three N-linked oligosaccharide
chains, which are mainly of complex-type. Here we report a
one-step purification method of Duffy protein from human
erythrocytes. DARC was extracted from erythrocyte mem-
branes in the presence of 1% n-dodecyl-β-D-maltoside
(DDM) and 0.05% cholesteryl hemisuccinate (CHS) and pu-
rified by affinity chromatography using immobilized anti-Fy6
2C3 mouse monoclonal antibody. Duffy glycoprotein was
eluted from the column with synthetic DFEDVWN peptide
containing epitope for 2C3 monoclonal antibody. In this
single-step immunoaffinity purification method we obtained
highly purified DARC, which migrates in SDS-polyacrylamide
gel as a major diffuse band corresponding to a molecular mass
of 40–47 kDa. In ELISA purified Duffy glycoprotein binds
anti-Duffy antibodies recognizing epitopes located on distinct
regions of the molecule. Results of circular dichroism measure-
ment indicate that purified DARC has a high content of α-
helical secondary structure typical for chemokine receptors.
Analysis of DARC glycans performed by means of lectin
blotting and glycosidase digestion suggests that native Duffy
N-glycans are mostly triantennary complex-type, terminated
with α2-3- and α2-6-linked sialic acid residues with bisecting
GlcNAc and α1-6-linked fucose at the core.
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Introduction
Duffy antigen is a transmembrane N-glycosylated protein
present mainly on erythrocytes and endothelial cells of post-
capillary venules of various tissues. Initially identified as a
blood group antigen, it was later characterized as a receptor
for Plasmodium vivax parasites and a promiscuous
chemokine-binding protein.
The polypeptide chain of the Duffy glycoprotein consists
of 336 amino-acid residues and spans cell membrane seven
times, creating three extra- and three intracellular loops. The
N-terminal glycosylated extracellular domain of DARC car-
ries the Fy
a and Fy
b Duffy blood group antigens, which differ
by an amino acid at position 42 (Fy
a - Gly, Fy
b - Asp), but
have a common Fy6 epitope [1–3]. The Fy6 epitopes, recog-
nized by a number of monoclonal antibodies, are located
within sequence
19QLDFEDVW
26 of the Duffy polypeptide
chain. Another common antigenic determinant Fy3 is located
on the third extracellular loop of the polypeptide chain of
Duffy glycoprotein [4–6]. The extracellular domain of DARC
is particularly interesting because it is involved in the interac-
tion with chemokines and P. vivax parasite [7–10].
Duffy antigen acts as a promiscuous receptor for a num-
ber of pro-inflammatory CC and CXC chemokines, there-
fore it is called the Duffy antigen/receptor for chemokines
(DARC) [7, 11]. Although structurally related to functional
chemokine receptors, it lacks the DRYLAIV motif on the
second intracellular loop and does not participate in G-
protein dependent signal transduction. For this reason it
was designated as a “silent” chemokine receptor or, more
recently, as a member of the atypical chemokine receptors
(ACR) family [12–15]. DARC is an important regulator of
inflammatory reactions, acting as a chemokine scavenger on
the surface of red blood cells, and expressed in endothelial
cells, as a regulator of induced leukocyte trafficking [16,
17]. It is postulated that it plays a protective role in cancer
formation and development by inhibiting angiogenesis of
the tumor tissue and metastasis [18, 19]. DARC might
participate in post-transplant inflammation of the kidney,
leading to graft rejection [20].
The role of the Duffy antigen is only partially elucidated.
A more detailed biophysical and structural characterization
is essential for understanding its various functions. To date,
the structure of Duffy glycoprotein has not been character-
ized due to difficulties in obtaining purified Duffy protein.
Several attempts have been made to purify the Duffy antigen
from human red blood cells [21–24], however, with only
limited success.
DARC is a sialylated glycoprotein containing N-linked
oligosaccharides, which has a strong tendency to form aggre-
gates, even under denaturing conditions, and migrates in
polyacrylamide gel as a wide 36–47 kDa band [22, 25, 26].
We have previously shown that DARC expressed in K562
cells is a glycoprotein with three N-linked oligosaccharide
chains, which are mostly of complex-type, rich in N-acetyl-
lactosamine units terminating with α2-6-linked sialic acid
residues, with α1-6-fucose at the N,N′-diacetylchitobiose
core [27, 28]. The aim of our present study was to develop
a procedure to purify the native DARC molecule from human
erythrocytes and to characterize the structure of its sugar
chains. Immunoaffinity purification using immobilized
monoclonal anti-Duffy antibody and synthetic peptide con-
taining epitope sequence for elution was considered to be the
most promising [29]. Here we describe the solubilization and
immunopurification of the DARC from human erythrocyte
membranes and the characterization of its N-linked oligosac-
charide chains. This is the first detailed study addressing the
purification and molecular characterization of the human
DARC and the structure of its N-glycan chains.
Materials and methods
Monoclonal antibodies
The following monoclonal antibodies, which epitopes were
characterized in our laboratory, were used: mouse anti-Fy6
i3A and 2C3 [4, 5], anti-GPA 4E4 [30], anti-Band3 136
[31], anti-Fy3 MIMA29, and human anti-Fy
a 5T72 [6].
Preparation of the anti-Duffy immunoaffinity column
To purify anti-Duffy antibody, hybridoma cells producing
anti-Fy6 2C3 monoclonal antibody were cultured in BD
Cell MAb Serum-Free Medium supplemented with 2 mM
GlutaMAX in BD CELLine 1000 system (BD Biosciences)
according to the manufacturer’s instructions. Adapted cells
grown in this medium remained living and were capable of
producing the 2C3 antibody for 8–10 weeks. This allowed
us to obtain ~120 mg of 2C3 MoAb, which was then
purified on Pierce Protein G Agarose (Pierce) and immobi-
lized on agarose beads using AminoLink plus Immobiliza-
tion Kit (Pierce) according to the manufacturer’s
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was immobilized on 10 ml of AminoLink resin with a
coupling efficiency of 98.2%. Anti-Fy6 resin was stored in
PBS containing 0.05% sodium azide at 4°C.
Preparation of the human erythrocyte ghosts
Human erythrocytes from outdated blood units were
obtained from the Regional Centre of Transfusion Medicine
and Blood Bank, Wrocław, Poland. Erythrocyte ghosts were
prepared from red blood cells using a modification of the
method of Steck et al.[ 32]. Briefly, red blood cells were
lysed in 10 volumes of ice-cold 5 mM phosphate buffer
pH 8.0 in the presence of 1 mM EDTA and 0.2 mM PMSF
(Sigma) for 10 min. Erythrocyte membranes were isolated
by recirculating the lysate in Pellicon Biomax Coarse 0.5 m
2
tangential flow cassette (pore size 1,000 kDa; Millipore) in
5 mM phosphate buffer pH 8.0, 1 mM EDTA, 0.2 mM
PMSF at 4°C until complete removal of the hemoglobin
[33]. The washed ghosts were concentrated by centrifuga-
tion at 14,000 × g for 45 min and stored at −80°C with
protease inhibitors: 5 μg/ml aprotinin, 5 μg/ml leupeptin,
0.1 mM Pefabloc (Roche) until further use.
Purification of the Duffy glycoprotein from human
erythrocytes
All purification steps were performed at 4°C in the presence
of protease inhibitors (5 μg/ml aprotinin, 5 μg/ml leupeptin
and 0.1 mM Pefabloc). Erythrocyte ghosts (200 ml) were
solubilized by incubation with an equal volume of 50 mM
Tris–HCl pH 7.4, containing 300 mM NaCl, 20% glycerol,
2% DDM and 0.1% CHS (Sigma) for 4 h on a rotator and
centrifuged at 27,000 × g, 45 min to remove the insolubi-
lized debris. The solubilized ghosts were incubated with
6 ml of resin with immobilized 2 C3 antibody overnight at
4°C on a rotator. After overnight incubation the resin was
centrifuged at 150 × g for 5 min to separate the supernatant
and the resin was transferred into a 20×1.5 cm glass col-
umn. The column was washed with 20 volumes of equili-
bration buffer 25 mM Tris–HCl pH 7.4, 150 mM NaCl, 10%
glycerol, 0.1% DDM, 0.005% CHS and bound Duffy pro-
tein was eluted from the column with 10 column volumes of
300 μg/ml of DFEDVWN custom synthetic peptide (Mim-
otopes) in equilibration buffer. Then the column was washed
with five column volumes of 0.1 M glycine pH 2.8, five
column volumes of 50 mM diethylamine pH 11, containing
0.5 M NaCl, 0.1% DDM, 10% glycerol, 1 mM Pefabloc,
and finally with 20 volumes of equilibration buffer. All
eluates were checked for the presence of Duffy glycoprotein
by western blotting using 2C3 antibody and Duffy-positive
fractions were combined. The DFEDVWN peptide was
removed from purified Duffy glycoprotein samples using
Zeba Spin Desalting Columns (Thermo Scientific) accord-
i n gt om a n u f a c t u r e r ’s instructions. Protein concentration
was determined using Picodrop spectrophotometer (Picodrop
Limited) and BCA assay [34]. Purified Duffy glycoprotein
was subjected to molecular characterization and oligosaccha-
ride chain analysis as described below.
Circular dichroism measurements
The CD spectroscopy was carried out on a Jasco J-600
spectropolarimeter (JASCO) with a 1 mm path length cell
cuvette at room temperature. The measurements were per-
formed on immunopurified Duffy glycoprotein at 4.33 μM
concentration in 0.05% DDM in PBS. The CD spectrum
which is given, is the mean of three scans.
ELISA measurements
Wells of MaxiSorp white opaque plates (Nunc) were coated
with 50 μl of purified DARC (2 μg/ml) in 60 mM NaHCO3
pH 9.6 overnight at 4°C. All subsequent steps were per-
formed at room temperature. The wells were blocked with
200 μl of 2% BSA, 0.1% Tween-20 in TBS for 1 h, washed
with 3×200 μl of TTBS and were subsequently incubated
for 2 h with 50 μl of monoclonal anti-Duffy or anti-GPA
antibody serially diluted in TTBS and then for 1 h with
50 μl of anti-mouse IgG or anti-human IgG antibody con-
jugated with horseradish peroxidase (HRP; Bio-Rad) diluted
in TTBS. After each incubation the wells were washed with
5×200 μl of TTBS. A chemiluminescent reaction was de-
veloped with 50 μl of SuperSignal ELISA Pico Chemilu-
minescent Substrate (Thermo Scientific) and measured
using Victor Light Luminescence Plate Reader (Perkin
Elmer). All tests were performed in duplicate.
SDS-PAGE and western blotting
Protein samples were incubated in SDS sample buffer at
room temperature for 10 min and subjected to electro-
phoresis in 12% polyacrylamide gels according to
Laemmli [35]. Following electrophoresis the gels were
either stained with 0.25% Coomassie Brilliant Blue R-
250 (Bio-Rad) [36] or proteins were electrophoretically
transferred to Immobilon-P membrane (Millipore) [37].
The blots were blocked for 4 h at room temperature with 5%
low-fat milk (Bio-Rad), 0.3% Tween-20 in TBS pH 7.4. Blot-
ted Duffy protein was identified by consecutive incubations
with anti-Fy6 2C3 monoclonal antibody (overnight at 4°C),
alkaline phosphatase-conjugated goat anti-mouse IgG anti-
body (Bio-Rad; 1 h, room temperature), and phosphatase
substrate solution: 0.15 mg/ml BCIP and 0.3 mg/ml NBT
(Bio-Rad) in 0.1 M Tris–HCl pH 9.5, 1 mM MgCl2 buffer.
After each step the blots were washed 5×7 min with TTBS
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Lectin blotting
Purified Duffy glycoprotein was subjected to SDS-PAGE
and transferred to Immobilon-P membrane. The membrane
was incubated overnight at 4°C in 0.5% Tween-20 in TBS.
Later the blots were incubated with digoxigenin-labeled
lectins Datura stramonium agglutinin (DSA), Galanthus
nivalis agglutinin (GNA), Sambucus nigra agglutinin
(SNA), and Maackia amurensis agglutinin (MAA; DIG
Glycan Differentiation Kit, Roche) 1 μg/ml each or biotin-
labeled lectins Aleuria aurantia agglutinin (AAA), Canava-
lia ensiformis agglutinin (ConA), Dolichos biflorus aggluti-
nin (DBA), Griffonia simplicifolia IB 4 lectin (GSL-I B4),
Griffonia simplicifolia II lectin (GSL-II), Lens culinaris
agglutinin (LCA), Phaseolus vulgaris erythroagglutinin
(PHA-E), Phaseolus vulgaris leukoagglutinin (PHA-L),
Pisum sativum agglutinin (PSA), Psathyrella velutina ag-
glutinin (PVA), Ricinus communis I agglutinin (RCA-I),
Glycine max agglutinin (soybean, SBA), Ulex europaeus
agglutinin (UEA), Wisteria floribunda agglutinin (WFA),
Triticum vulgaris agglutinin (wheat germ, WGA; Vector
Laboratories) 5 μg/ml each in 0.5% Tween-20/TBS pH 7.4
or pH 8.0 for AAA, with 1 mM MgCl2, 1 mM MnCl2, 1m M
CaCl2 and 0.5 M NaCl for WGA. Incubation was performed
at room temperature for 2 h with gentle shaking. The blots
were washed 5×10 min with 0.5% Tween-20 in TBS and
1×10 min with 0.1% Tween-20 in TBS, and incubated with
either anti-digoxigenin-alkaline phosphatase conjugate
1,000-fold diluted (Roche) or alkaline phosphatase-
conjugated streptavidin 1,000-fold diluted (Vector Labora-
tories) in 0.1% Tween-20 in TBS for 1 h at room tempera-
ture with gentle shaking. After washing the blots 4×10 min
with 0.1% Tween-20 in TBS and 2×10 min with TBS, color
reaction was developed using standard BCIP/NBT
conditions.
The specificity of selected lectins binding was verified by
using lectins preincubated for 2 h at room temperature in
buffer containing 0.7 M L-fucose (for AAA; Sigma), 0.5 M
α-methyl-D-mannopyranoside (for LCA; Sigma), 0.5 M ga-
lactose (for RCA-I; Merck) and 0.5 M N-acetylglycosamine
(for WGA; Sigma). The specificities of MAA, SNA, RCA-I,
GSL-II and PVL were studied by their reaction with the
blotted Duffy protein after consecutive removal of sialic
acid and galactose residues. The lectins and their specific-
ities are listed in Table 1.
Modification of the blotted glycoproteins
Desialylation was performed by incubating the blots after
protein transfer with 0.025 M sulfuric acid for 1 h at 80°C.
Degalactosylation was performed after desialylation by in-
cubating the blots successively in (i) 0.05 M NaIO4 in 0.1 M
acetate buffer, pH 4.5, overnight at 4°C, (ii) 0.15 M NaBH4
in 0.1 M sodium borate buffer, pH 8.0, for 2–3 h at 20°C,
and (iii) 0.025 M sulfuric acid for 1 h at 80°C. Each
incubation was followed by washing the blots with water
[38]. After modification, the blots were blocked and ana-
lyzed by lectin binding.
Endo- and exoglycosidase digestion
Glycosidase digestions were performed following protocols
provided by the enzyme suppliers. Before enzyme treat-
ment, the buffer in Duffy samples was changed to digestion
buffer using Zeba Spin Desalting Columns (Thermo Scien-
tific). Duffy protein was incubated overnight at 37°C with:
PNGase F, endo-β-galactosidase, endoglycosidases F1, F2
and F3 (Sigma, Calbiochem) and neuraminidases from
Newcastle disease virus (NDV; Genzyme) or from Arthro-
bacter ureafaciens (ABS; Sigma) in the presence of protease
inhibitors Complete, EDTA-free Protease Inhibitor Cocktail
Tablets (Roche) and Protease Inhibitor Cocktail (Sigma).
The reaction was terminated by chilling the samples at 4°C
and adding Laemmli electrophoresis sample buffer [35].
Digested glycoprotein was analyzed by immunoblotting.
Results
Purification of the human DARC by anti-Fy6 affinity
chromatography
In order to isolate Duffy glycoprotein from human erythro-
cyte membranes, several detergent mixtures were tested.
Similarly to other chemokine receptors [28, 39–41] a com-
bination of 1% DDM and 0.05% CHS was found to be
optimal for solubilizing and stabilizing the Duffy protein.
Duffy antigen was retained from the ghost detergent extract
on the immobilized 2C3 MoAb column. It was eluted in
three to five column volumes during development with
mobile phase containing DFEDVWN peptide. Only a small
amount of Duffy antigen was eluted from the column with
50 mM diethylamine, 0.5 M NaCl, 0.1% DDM, 10% glyc-
erol, 1 mM Pefabloc pH 11 or 0.1 M glycine pH 2.8. This
indicates that elution with DFEDVWN peptide solution in
the column buffer is highly efficient and nearly complete.
Starting with 200 ml of erythrocyte membranes contain-
ing ~800 mg of total protein we routinely obtained ca.
500–800 μg of purified DARC protein.
Analysis of purified DARC in SDS-PAGE by CBB stain-
ing revealed the presence of a diffuse protein band with a
molecular mass of 40 to 47 kDa (Fig. 1a, lane 3) and faint
bands, which may be contaminants or aggregated Duffy
96 Glycoconj J (2012) 29:93–105protein. In western blotting analysis of affinity purified
Duffy glycoprotein, the anti-Fy6 MoAb detected 40–
47 kDa Duffy monomer, accompanied by the diffused stain-
ing of the upper part of the blot (Fig. 1b). This pattern of
staining is typical for the Duffy protein [21, 22, 25, 28, 29]
and can represent self-association of this extremely hydro-
phobic protein into higher molecular weight oligomers.
Analyzing the blots with anti-GPA and anti-Band 3 anti-
bodies showed that purified Duffy protein did not contain
GPA and contained only traces of Band 3 oligomers (Fig. 1b
lane 3). Comparing the ghost lysate and the flow through
from the affinity column showed the selective adsorption of
most Duffy protein and no visible change in the content of
total proteins, GPA or Band 3 (Fig. 1, lanes 1 and 2).
Secondary structure and interaction with antibodies
The circular dichroism (CD) spectrum of Duffy glycopro-
tein showed two negative maxima at 208 nm and 222 nm
(Fig. 2), typical for a member of the GPCR family. Similar
spectra were obtained for other chemokine receptors [42,
43]. The CD profile of purified DARC suggests a high
Table 1 Binding of lectins to
purified DARC. +++ strong
binding, ++ average binding, +
weak binding, - no binding.
* - after desialylation, ** - after
desialylation and
degalactosylation
aLectin specificities according to
Wu et al. 2001 [59].
Lectin Recognized structure
a Binding
to DARC
AAA α1-6-Fuc > α1-2,3-Fuc +++
Aleuria aurantia agglutinin
ConA (Concanavalin A) αMan residues with unsubstituted C3, C4 and
C6; trimannosidic N-glycan core with or
without bisecting β1-4-linked GlcNAc
+
Canavalia ensiformis agglutinin
DBA GalNAc residues −
Dolichos biflorus agglutinin
DSA Galβ1-4GlcNAc (N-acetyllactosamine) residues,
tri- and tetraantennary complex-type N-glycan
+++
Datura stramonium agglutinin
GNA terminal α1-3-linked Man −
Galanthus nivalis agglutinin
GSL-I B4 Galα1-3Gal residues −
Griffonia simplicifolia IB 4 lectin
GSL-II GlcNAc residues +++**
Griffonia simplicifolia II lectin
LCA bi- and triantennary complex-type N-glycan with
α1-6-linked core fucose
+++
Lens culinaris agglutinin
MAA α2-3-Neu5Ac, SO4-3Galβ1-4GlcNAc ++
Maackia amurensis agglutinin
PHA-E bi- and triantennary complex-type N-glycans with
bisecting GlcNAc
+++
Phaseolus vulgaris erythroagglutinin
PHA-L tri- and tetraantennary complex-type N-glycans −
Phaseolus vulgaris leukoagglutinin
PSA bi- and triantennary complex-type N-glycan with
α1-6-linked core fucose
+++
Pisum sativum agglutinin
PVL GlcNAc residues, α2-3-Neu5Ac +++
Psathyrella velutina lectin
RCA-I terminal Gal +++*
Ricinus communis I agglutinin
SBA GalNAc residues −
Glycine max (Soy bean) agglutinin
SNA α2-6-Neu5Ac +++
Sambucus nigra agglutinin
UEA-I α1-2-Fuc −
Ulex europaeus I agglutinin
WFA terminal α/βGalNAc −
Wisteria floribunda agglutinin
WGA GlcNAcβ1-4 polymers, Neu5Ac residues ++
Triticum vulgaris (Wheat germ) agglutinin
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48% using the equation: %a helix ¼ θ ½  208nm  
4000=33000   4000 [44]. This result is very close to a
theoretical 50% α-helix content for a GPCR and suggests
that purified DARC retains the secondary structure charac-
teristic of a chemokine receptor.
The ability of purified Duffy glycoprotein to interact with
ligands was analyzed with chemiluminescent ELISA on
DARC-coated plates using anti-Duffy antibodies. The anti-
Duffy antibodies chosen for the ELISA tests recognize
different linear epitopes, Fy6, Fy3 and Fy
a. All anti-Duffy
monoclonal antibodies, which were tested interacted with
immunopurified DARC immobilized on ELISA plate
(Fig. 3). This indicated that all analyzed antigenic determi-
nants located in distinct regions of the Duffy molecule were
accessible for the antibodies. As a negative control 4E4
monoclonal antibody recognizing amino acid residues
119–124 at the C-terminal part of glycophorin A was used.
No reaction with this antibody was observed (Fig. 3)
confirming the absence of contamination of the purified
DARC sample with GPA.
Analysis of DARC N-glycans by endoglycosidase digestion
To characterize the glycan part of DARC, purified Duffy
glycoprotein was treated with glycosidases and the effects of
digestion on molecular mass were assessed by western
blotting. As shown in Fig. 4a digesting Duffy glycoprotein
with PNGase F, which cleaves all N-linked oligosacchar-
ides, resulted in a molecular mass change from ~40–47 kDa
(native form) to ~28–30 kDa indicating that the molecular
mass of the three DARC N-glycan chains is ~18 kDa. In
addition, bands representing higher molecular masses of
~65–70 kDa, ~130 kDa and ~250 kDa (Fig. 4a,l a n e
PNGase F) were also observed. These bands are probably
products of oligomerisation of the Duffy glycoprotein
resulting from the incubation with the enzyme at 37°C and
may represent dimer, trimer, tetramer or high oligomers of
deglycosylated Duffy protein. It cannot be excluded that
removing the three N-glycans from the polypeptide chain
of DARC increases the potential of this glycoprotein to form
aggregates. Treating the sample with endoglycosidase F1,
removing high-mannose and hybrid type N-glycans,
resulted in only partial digestion, which could be observed
as a faint band corresponding to a molecular mass of about
30 kDa, close to that of a completely deglycosylated form of
the protein. On the other hand, incubating the Duffy glyco-
protein with endoglycosidase F2, cleaving high-mannose
and biantennary complex-type N-glycans, had no effect on
the molecular mass of DARC. Taken together this could
suggest that Duffy glycoprotein does not contain high man-
nose chains, but a small number of DARC molecules pres-
ent in the sample have hybrid-type N-glycans. Treating
DARC samples with endoglycosidase F3, which cleaves
bi- and triantennary complex-type N-glycans, resulted in
shifting the molecular mass corresponding to the Duffy
Fig. 1 The efficiency of
immunopurification of the
Duffy antigen tested by SDS-
PAGE, followed by CBB stain-
ing (a) or immunoblotting (b).
Lanes: 1, dodecyl-β-maltoside
solubilized ghosts; 2, anti-Fy6
affinity flow through (unbound
erythrocyte membrane extract);
3, anti-Fy6 affinity DFEDVWN
peptide eluate (b) Proteins
transferred to Immobilon-P
membrane were identified with
anti-Fy6, anti-GPA, anti-Band3
monoclonal antibodies. Lanes
numbered 1, 2 and 3 were
loaded with same material as
used for CBB stained gel
Fig. 2 Circular dichroism spectroscopy of purified Duffy glycoprotein
(4.33 μM in 0.05% DDM, PBS). CD spectrum reveals two negative
maxima at 208 nm and 222 nm characteristic for GPCR receptors
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PNGase F digestion. This could suggest that most of the
oligosaccharide chains of Duffy antigen are complex-type
structures. The small difference in the electrophoretic mo-
bility of DARC after PNGase F and endoglycosidase F3
treatment is difficult to explain. It does not depend on
enzyme activity or concentration but it could be related to
different sites of cleaving: PNGase F is hydrolyzing the
intact N-glycans directly from asparagine of the polypeptide
chain while endoglycosidase F3 cleaves the bond between
two GlcNAc residues in the chitobiose core of N-glycan.
The removal of Duffy N-glycans due to PNGase F and
endoglycosidase F3 digestion was confirmed by probing
the digested DARC with Datura stramonium lectin. This
lectin recognizes mostly complex-type N-glycans. We found
that it strongly reacts with the recombinant form of the
Duffy antigen [28] and with that from erythrocytes as well
(Fig. 5b). No reaction with DSA was observed in western
blotting after PNGase F and endoglycosidase F3 treatment
(Fig. 4b).
To study the presence of N-acetyllactosamine units in
DARC oligosaccharides, we digested purified Duffy glyco-
protein with endo-β-galactosidase, which releases the β1-4-
linked galactose in unbranched repeating GlcNAcβ(1–3)
Galβ(1–4)GlcNAc structures. After enzyme treatment a
slight decrease in molecular mass of Duffy bands was ob-
served in western blotting (Fig. 4a) suggesting the presence
of a small population of the endo-β-galactosidase-sensitive
carbohydrate chains in Duffy glycoprotein. Interestingly,
after endo-β-galactosidase treatment, Duffy bands gave a
strong signal with DSA (Fig. 4b), which binds specifically
to Galβ(1–4)GlcNAc, suggesting that a certain number of
N-acetyllactosamine units present in analyzed N-glycans
might be resistant to enzyme digestion. This may be due
to the degree of branching or fucosylation of oligosachar-
ides or sulfation of galactose.
Analysis of human Duffy glycoprotein oligosaccharide
chains with lectins
N-linked oligosaccharide chains of the human Duffy antigen
from erythrocytes were analyzed by probing DARC glyco-
protein with lectins in lectin blotting. Duffy glycoprotein
was detected on the blots using anti-Duffy monoclonal
antibody (2C3) and lectin blotting assays were performed
in parallel. A positive reaction was found with SNA and
MAA, which specifically recognize sialic acid linked α2-6
or α2-3 to galactose, respectively. To confirm the presence
of both α2-3 and α2-6 sialic acid residues Duffy glycopro-
tein was digested with ABS (cleaves α2-3,6,8,9-linked
Neu5Ac) and NDV (cleaves α2-3,8-linked Neu5Ac) siali-
dases and analyzed by western blotting. In immunoblotting
with 2C3 MoAb a small molecular mass shift was observed
after treating DARC with ABS or NDV sialidase. No reac-
tion with MAA recognizing α2-3-linked sialic acid residues
was observed in both digested samples, while SNA reacted
with untreated and NDV-treated Duffy antigen (Fig. 4c).
These results confirm the presence of α2-6- and α2-3-
linked sialic acid residues. The possible presence of sialic
acids in α2-8 or α2-9 linkages in DARC from human
erythrocytes cannot be excluded. However, a significant
molecular mass shift after ABS digestion, which could
result from the presence of such polymers, was not observed
in western blotting developed with 2C3 MoAb or lectins. As
shown in Fig. 5a the binding of SNA and MAA to Duffy
antigen oligosaccharides was abolished after removing sialic
acid from the blotted protein by mild acid hydrolysis. This
confirmed the specificity of these interactions.
Fig. 3 Binding of anti-Duffy
(anti-Fy6 i3A, anti-Fy3 MIMA
29, anti Fy
a 5T72) monoclonal
antibodies to the wells of
ELISA plates coated with puri-
fied DARC. Binding of irrele-
vant antibody anti-GPA 4E4
was also analyzed. Binding was
determined using HRP-labeled
antibodies directed against
mouse or human IgG. Chemi-
luminescent reaction was de-
veloped with SuperSignal
ELISA Pico Chemiluminescent
Substrate and measured on a
Victor Light Microplate
Luminometer. CPS - counts per
second
Glycoconj J (2012) 29:93–105 99RCA, which is specific for terminal galactose residues,
particularly in Galβ1-4GlcNAc units, reacted with the
Duffy bands only after desialylation. Desialylation and
degalactosylation, which removed terminal Gal residues
from the blotted protein abolished the reaction with RCA
and enabled a reaction with GlcNAc-recognizing GSL-II
(Fig. 5a).
No reaction of Duffy glycoprotein was observed with
GNA, which recognizes terminal α-linked mannose resi-
dues typical for oligomannose and hybrid-type N-glycans.
Only weak binding was observed for Concanavalin A
(Fig. 5a). This may confirm the lack of oligomannose chains
among DARC glycans, suggested also by the results of
endoglycosidase F1 and F3 digestion. ConA has the stron-
gest affinity for α-Man residues with unsubstituted C3, C4
and C6 but it also shows some weak interaction with the
three mannose residues at the N-glycan core, however not in
the presence of bisecting GlcNAc.
Other lectins such as DSA, PSA, PHA-E and PHA-L
recognize more specific aspects of N-glycan structures.
The Duffy glycoprotein exhibited a strong interaction with
DSA, which specifically binds N-acetyllactosamine units
Fig. 4 Western blotting
analysis of purified Duffy
glycoprotein treated with
endoglycosidases or sialidases.
Purified Duffy antigen treated
with PNGase F, or
endoglycosidase F1, F2, or F3,
or endo-β-galactosidase was
identified with 2C3 anti-Fy6
monoclonal antibody (a)o r
DSA agglutinin (b). Purified
Duffy antigen treated with sia-
lidase from Newcastle disease
virus (NDV) or from Arthro-
bacter ureafaciens (ABS), was
identified with 2C3 anti-Fy6
monoclonal antibody or MAA
and SNA agglutinins (c)
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(Fig. 5b). This has also been observed with recombinant
DARC from transfected K562 cells [28]. Very strong
binding of PHA-E, which binds “bisected” complex-type
N-glycans and the lack of binding of PHA-L specific for
complex-type N-glycans containing 2,6-branched structure
(Fig. 5b) suggested that native DARC oligosaccharides are
bi- or triantennary complex-type N-glycans with bisecting
GlcNAc, which confirmed results obtained by endoglyco-
sidase F3 digestion. A strong reaction was also observed
for PSA (Fig. 5b) and LCA (Fig. 5c) recognizing core-
fucosylated complex-type N-glycans. To verify the pres-
ence of L-fucose, often found in hybrid- and complex-
type N-glycan chains, AAA and UEA-I were used in
lectin blotting. A very strong reaction with AAA
(Fig. 5c), recognizing α1-2-, α1-3- and particularly α1-
6-linked Fuc, indicates the presence of a significant quan-
tity of fucose in DARC oligosaccharides. UEA-I, which is
specific for α1-2-linked Fuc, did not react with Duffy
antigen. This implies that most of the fucose residues
may be α1-6-linked to N-acetylglucosamine at the N-gly-
can core. This hypothesis is supported by the strong
binding of LCA and PSA, which recognize bi- and tri-
antennary complex-type N-glycans but require the pres-
ence of α1-6 core fucose for this interaction. The
specificity of reaction with AAA and LCA was confirmed
by preincubating the lectins with excess of competing
sugars (L-fucose and α-methyl-mannopyranoside respec-
tively), which totally inhibited binding the lectins to Duffy
(Fig. 5c). GalNAc-specific lectins DBA, SBA and WFA,
as well as GSL-I, which recognize Galα1-3Gal, showed
no interaction with Duffy glycoprotein (not shown). We
believe that the presence of these glycan structures in
complex N-linked oligosaccharides of DARC from human
erythrocytes is not very probable. The results of the lectin-
binding analysis are summarized in Table 1.
Fig. 5 Binding of sialic acid-,
Gal-, GalNAc-, GlcNAc- and
mannose-specific lectins to pu-
rified DARC and to DARC
modified by desialylation (⋆)o r
degalactosylation (⋆⋆) on the
blot (a). Reaction of the blotted
Duffy glycoprotein with lectins
recognizing complex-type
branched N-glycans (b). Bind-
ing of Aleuria aurantia and
Lens culinaris agglutinins to
purified DARC. After protein
transfer and blocking the blots
were incubated in the absence
(−) or presence (+) of compet-
ing sugar: 0.7 M L-fucose for
AAA and 0.5 M methyl α-D-
mannopyranoside for LCA (c)
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Obtaining purified Duffy protein is very difficult due to its
low content (10–12×10
3 copies per cell) on erythrocytes
and strong tendency of native Duffy to form homo- and
hetero-oligomers, which leads to great protein losses during
purification [21, 22, 24, 25]. The same applies to recombi-
nant Duffy protein and chemokine receptors since there is
no efficient system of expression. For these reasons, of over
20 chemokine receptors and chemokine binding proteins
only a few molecules have been obtained in quantities
sufficient to perform molecular characterization [39–43].
Recently, the crystal structure of the first chemokine recep-
tor CXCR4 in complex with small molecular antagonists
has been reported. On the basis of the results of crystallo-
graphic analysis the mechanism of CXCR4 interaction with
its ligands was proposed [45].
A detailed description of the molecular structure of the
Duffy glycoprotein is crucial for understanding the mecha-
nisms of its interactions with ligands and explaining its bio-
logical role. Inthis study weundertook the efforttopurifyand
characterize the native Duffy glycoprotein from human eryth-
rocytes. We solubilized DARC under the same conditions as
were previously applied for the isolation and purification of
the functional atypical chemokine receptor D6 [39] and che-
mokine receptors CCR1 [41] and CXCR4 [40, 45]. This
involved a combination of 1% DDM and 0.05% CHS in
extraction buffer, which very effectively solubilizes the pro-
teinfromcellmembranesandpreventsitsself-aggregation.To
purify Duffy glycoprotein from the detergent extract we used
an immobilized anti-Duffy mouse monoclonal antibody for
adsorption and a synthetic peptide DFEDVWN covering the
sequence of the antibody epitope for elution of bound protein.
This allowed us to obtain highly purified Duffy glycoprotein
essentially free of other proteins of the RBC membrane. Anti-
Fy6 antibodies were used as an affinity reagent to purify the
Duffy antigen from Triton extract of red cell membranes [21,
24]. Recently, an immunoadsorbent prepared with anti-Fy6
recombinant CA52 dromedary antibody fragment and peptide
containing epitope sequence for elution have been successful-
ly used for the purification of a recombinant DARC in small-
scale experiments [29]. The novelty of our method in relation
to the previously described conditions for isolation and
purification of Duffy antigen was the application of deter-
gent DDM and CHS mixture, which help to maintain
correctly folded protein structure after purification. We have
shown this by CD measurements. Additionally, elution of
bound Duffy protein with epitope peptide solution helps to
keep protein in its native state since it is not exposed to
harsh elution conditions commonly used for elution of
immunoadsorbents.
Glycosylation is the most common form of posttransla-
tional modification of proteins in eukaryotes and analysis of
the protein sequence data bank reveals that significant pro-
portions of proteins do contain sequence patterns suggesting
that they might be glycosylated. To date, the glycosylation
of few chemokine receptors and D6 atypical receptor has
been reported. It was shown to be important for ligand
binding and HIV entry through the CCR5 and CXCR4
receptors [46, 47] while it is not required for chemokines
binding by DARC or D6 atypical chemokine receptor [9,
39, 48]. Glycosylation is significant for protein folding and
stability and may be important for chemokine physiology,
but the oligosaccharide chain structures of chemokine recep-
tors are still unknown.
Erythrocyte membrane glycoproteins show different types
of glycosylation but often are decorated with complex-type
oligosaccharides with various degree of branching. Glyco-
phorin A (GPA), an abundant sialoglycoprotein of RBCs is
highly O-glycosylated and contains one N-linked chain per
molecule. The major form of GPA N-glycan is a relatively
short α2-6-sialylated biantennary chain with bisecting
GlcNAc residue of molecular mass ~2,400 Da [49, 50]. A
minor fraction of GPA N-glycan pool was found to contain
blood group ABH epitopes [51].On the other hand, the multi-
membrane spanning glycoproteins Band 3 (anion transporter)
andBand4.5(glucosetransporterGlut1)havelargeN-glycans
withpolyllactosamine-typeantennae,whicharemajorcarriers
of ABH blood group determinants [52–57]. The results of our
study, i.e. lack of binding of lectins such as UEA-I, DBA,
GSL-I, SBA, WFA to purified DARC, indicate the absence of
ABH blood group epitopes in oligosaccharides of the Duffy
antigen. However, it is possible that to detect only minute
amounts of these carbohydrate structures more sensitive mass
spectrometry methods would be necessary for greater preci-
sion and accuracy.
The results of this study obtained by means of lectins and
endoglycosidase digestion indicate that the sugar chains of
Duffy glycoprotein from red blood cells are mostly trianten-
nary complex-type terminated with α2-3- and α2-6-linked
sialic acid residues with bisecting GlcNAc and α1-6-linked
fucose at the core. There is no observed evidence suggesting
the presence of oligomannose-type chains. The structures of
DARC N-glycans may differ by number of lactosamine
units in their antannae, degree of branching and some minor
modifications such as the presence of bisecting GlcNAc or
different combinations of terminal sialic acid residues. The
decrease of apparent molecular mass of deglycosylated
Duffy glycoprotein gives an average molecular mass of N-
glycans ~6,000 Da that strongly suggests that these glycans
have antennae elongated by repeating lactosamine units and
are more similar to N-glycans of Band 3 and Band 4.5 than
to GPA N-glycan.
This is also supported by the results of digestion with
endo-β-galactosidase and strong reaction with DSA lectin,
however the oligosaccharide structure recognized by DSA
102 Glycoconj J (2012) 29:93–105was not readily accessible to endo-β-galactosidase therefore
DSA reacted strongly after enzyme digestion. In contrast,
linear N-acetyllactosaminyl glycans present in Band 3
and Band 4.5 are released by endo-β-galactosidase
[58]. Presence of poly-N-acetyllactosamine units in na-
tive Duffy antigen from human erythrocytes is highly
possible but these oligosaccharides may differ from those
of Band 3 and Band 4.5 in branching or sulfation of
galactose residue [52, 55]. Since the molecular mass shift
observed for DARC after treatment with endo-β-
galactosidase is not very significant, the lactosamine
units present in this glycoprotein are possibly not as
extended as the structures found in Band 3.
In our earlier studies we showed that recombinant Duffy
glycoprotein has N-glycans attached at the three potential
glycosylation sites at Asn16, Asn27 and Asn33 and the N-
oligosaccharide chains were characterized [27, 28]. A com-
parison of N-glycans from recombinant and native Duffy
glycoprotein indicates that both are heterogenic, mainly
complex-type N-oligosaccharide chains with varying degree
of branching. Minor differences in sugar moieties structure
concern the type of sialic acid linkage. Recombinant Duffy
N-glycans lack sialic acids in α2-3 linkage while native
Duffy glycoprotein contains α2-6- and α2-3-linked sialic
acid residues.
In conclusion, DARC was solubilized with n-dodecyl-β-
D-maltoside from human erythrocyte membranes and puri-
fied using immunoaffinity chromatography. Using this pro-
cedure 500–800 μg of purified DARC can be obtained from
detergent solubilized 200 ml of erythrocyte membranes.
Purified DARC is recognized by several anti-Duffy mono-
clonal antibodies directed against different parts of the
DARC polypeptide chain. The expected high content of α-
helical structure was confirmed by CD measurements. Oli-
gosaccharide chains of DARC were characterized by means
of lectins and endoglycosidase digestion. Duffy N-glycans
are bi- and/or triantennary complex-type, terminated with
α2-3- and α2-6-linked sialic acid residues with bisecting
GlcNAc and α1-6-linked fucose at the core. This type of
large oligosaccharide chain may be characteristic for multi-
membrane spanning glycoproteins of red blood cells mem-
brane. These findings make a significant contribution to the
description of Duffy glycan moieties.
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